17:34 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; lung cancer Patient sample and mouse studies suggest miR-130a and miR-145 or their mimics could help treat breast and lung cancers. In tumor samples from patients with breast or lung cancers, low levels...
07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: microRNA-145 (miR-145)

Cardiovascular disease INDICATION: Hypertension; Pulmonary Rat studies suggest cationic lipopolyamine-based nanoparticles loaded with small RNA-based therapeutics could help treat pulmonary arterial hypertension (PAH) and other lung diseases. In a rat model of PAH, nanoparticles loaded with an...
07:00 , Jun 25, 2015 |  BC Innovations  |  Translation in Brief

Celsion's silent approach

Drug delivery Celsion Corp. (NASDAQ: CLSN) has discovered that its TheraSilence delivery platform delivers RNA-based therapeutics efficiently to the lung - a feat beyond most RNA delivery systems, which on the whole reach only the liver....
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Egen preclinical data

In a rat model of PAH, IV administration of a microRNA-145 inhibitor using Egen's Staramine-mPEG delivery system significantly reversed pulmonary hypertension and improved cardiovascular function. Data were presented at the American Thoracic Society meeting...
07:00 , Apr 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer ADAM17; microRNA-145 (miR-145); SRY (sex determining region Y)-box 9 (SOX9); IL-6 Mouse and...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

miRagen, University of Glasgow deal

The university granted miRagen exclusive rights to IP covering microRNA-145. The IP was discovered under a deal between the university, biotech and University of Cambridge (Cambridge, U.K.) to develop the target to treat...
08:00 , Jan 13, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer MicroRNA-143 (miR-143); miR-145 Studies in mice and in zebrafish suggest...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

Geniom Real Time Analyzer: Postmarketing study data

GRTA identified 165 miRNAs that were significantly up- or down-regulated in patients with relapsing-remitting MS (RRMS) vs. healthy controls. The most significantly deregulated biomarker, has-miR-145, discriminated between RRMS patients and healthy controls with 89.7% accuracy,...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms MicroRNA-145 to control...